UK Could Block Activist Plans To Shake Up GSK
New Law Allows Intervention
Executive Summary
GlaxoSmithKline is under attack from an activist investor, but as a key UK company, the government could use new powers to block any deals “not in the national interest”.
You may also be interested in...
Private Equity Eyes Pharma As Vectura Gets Snapped Up By Carlyle
Cash-rich private equity firms are eyeing opportunities in healthcare, especially among listed companies with sluggish share prices. The Carlyle Group could be getting a bargain if it seals a deal for the Chippenham-based inhalation specialist.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.